Patient Information

If you’ve been diagnosed with UC, you are likely dealing with a variety of emotions and questions:

  • Will my daily activities be disrupted?
  • How will this lifelong illness affect my life?
  • What medicines are available to relieve my pain and discomfort?

Well, you’re not alone.  Some 500,000 Americans live with UC, an Inflammatory Bowel Disease (IBD) that affects the colon, also called the large intestine. UC causes inflammation and ulcers in the lining of the rectum and colon.

Currently, there is no medicinal cure for UC. Treatment primarily involves the use of medications to relieve symptoms during periods when the disease is active, known as flares, and to help encourage remission, or the time when the disease is not active.

Talk to your doctor about treating flare symptoms with the
ROWASA® (mesalamine) Rectal Suspension Enema 4.0g/60mL Kit*,
and if it is right for you.

You can be flare ready with fast and soothing flare relief.

The ROWASA Kit*:

  • Contains only 2 ounces of medication in an easy to use bottle.
  • Targets the site of inflammation – coating the lining of the rectum and left side of the colon.
  • Reduces rectal bleeding in as little as 3 days.1
  • Provides relief of other common flare symptoms, including diarrhea and abdominal pain.2
  • Works while you sleep - nightly use of ROWASA allows for greater flexibility to fit into your daily regimen.
  • Improves quality of life: 87% of patients trying 5-ASA rectal therapy for the first time agreed.3
  • Is the most effective therapy for left-sided UC.4
  • Comes in a Kit* with a personal, daily cleansing wipe to keep you clean and fresh for those inevitable restroom stops.*

Stop flares fast with the ROWASA Kit*.

*Wipe is optional and not a required part of treatment.

Download this as a Patient Information Fact Sheet

1 Sutherland LR, Martin F, Greer S, et al. 5-aminosalicylic acid enema in the treatment
of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology.
1987;92(6):1894-1898.
2 ROWASA Prescribing Information
3 Biddle W, Miner P.B. Lifestyle Issues: Impact of enema therapy. Poster Abstract.
Falk Symposium No. 56, 1990.
4 Hanauer, SH: Inflammatory Bowel Disease. ACP Medicine 2005;4;1-23.
 
Home  |  Stay Up-to-Date  |  About Alaven  |  Privacy Policy  |  Contact Us

Important Safety Information
Contraindications: ROWASA® (mesalamine) Rectal Suspension Enema is contraindicated for patients known to have hypersensitivity to the drug or any component of this medication.
Warning: ROWASA® (mesalamine) Rectal Suspension Enema contains potassium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but probably low.
Precautions: Mesalamine has been implicated in the production of an acute intolerance syndrome characterized by cramping, acute abdominal pain and bloody diarrhea, sometimes fever, headache and a rash; in such cases prompt withdrawal is required. Caution should be exercised when mesalamine is initially used in patients known to be allergic to sulfasalazine.
Adverse Reactions: ROWASA® (mesalamine) Rectal Suspension Enema is usually well tolerated. Most adverse effects have been mild and transient. The most frequently reported adverse events include abdominal cramps, headache, gas, nausea, flu, fatigue, fever and rash.

The current formulation of ROWASA (mesalamine) is approved by the FDA for the treatment of mild to moderate distal ulcerative colitis, proctosigmoiditis, or ulcerative proctitis and is manufactured and marketed by Alaven Pharmaceutical. Click here for full prescribing information >>
© 2008 Alaven® Pharmaceutical LLC, Marietta, GA. All rights reserved.
ROWASA® is a registered trademark of Alaven® Pharmaceutical LLC.